X4 Pharmaceuticals, Inc.
XFOR
$4.02
$0.030.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.45% | 45.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.45% | 45.50% | |||
| Cost of Revenue | 64.29% | 3.70% | |||
| Gross Profit | -4.26% | 55.87% | |||
| SG&A Expenses | -6.14% | -9.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.19% | 8.59% | |||
| Operating Income | 15.19% | -5.71% | |||
| Income Before Tax | 15.40% | 19.84% | |||
| Income Tax Expenses | -- | 100.00% | |||
| Earnings from Continuing Operations | 15.40% | 19.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.40% | 19.76% | |||
| EBIT | 15.19% | -5.71% | |||
| EBITDA | 15.33% | -5.76% | |||
| EPS Basic | 62.82% | 37.43% | |||
| Normalized Basic EPS | 63.19% | 24.59% | |||
| EPS Diluted | 62.88% | 37.41% | |||
| Normalized Diluted EPS | 63.19% | 24.59% | |||
| Average Basic Shares Outstanding | 13.32% | 157.54% | |||
| Average Diluted Shares Outstanding | 13.32% | 157.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||